The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome

Journal of Nephropathology

Volumn 2, Issue 2, 2013, Pages 114-121

  Nishimura, Misato ^a   Nii, Tokiko ^a   Trimova, Gulzhan ^a   Miura, Shuhei ^a   Umezawa, Kazuo ^b   Ushiyama, Akira ^c   Kubota, Tetsuo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

Antiphospholipid syndrome; NF kappa B; Thrombosis; Tissue factor

Indexed keywords

EID: 84883058074     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.12860/JNP.2013.19     Document Type: Article

References (30)

1. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346(10):752-63.
2. Edwards CJ, Hughes GRV. Hughes syndrome (the antiphospholipid syndrome): 25 years old. Mod Rheumatol 2008;18(2):119-24.
3. Sangle S, D’Cruz D, Khamashta M, Tungekar MF, Abbs I, Hughes G. Goldblatt’s kidney, Hughes syndrome and hypertension. Lupus 2002;11(11):699-703.
4. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4(2):295-306.
5. Nasri H. Hypertension and renal failure with right arm pulse weakness in a 65 years old man. J Nephropathology 2012;1(3):130-3.
6. Pengo V, Ruiz-Irastorza G, Denas G, Andreoli L, Khamashta M, Tincani A. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’. Autoimmun Rev 2012;11(8):577-80.
7. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011; 270(2):110-22.
8. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, et al. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39(9):1466-74.
9. de Laat HB, Derksen RHWM, Urbanus RT, Roest M, de Groot PG. β2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104(12):3598-602.
10. Reverter J-C, Tàssies D, Font J, Khamashta MA, Ichikawa K, Cervera R, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998; 41(8):1420-7.
11. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52(5):1545-54.
12. López-Pedrera C, Buendía P, Cuadrado MJ, Siendones E, Aguirre MA, Barbarroja N, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-κB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK- 1/ERK pathway. Arthritis Rheum 2006; 54(1):301-11.
13. Sorice M, Longo A, Capozzi A, Garofalo T, Misasi R, Alessandri C, et al. Anti-β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56(8):2687-97.
14. Conti F, Sorice M, Circella A, Alessandri C, Pittoni V, Caronti B, et al. Beta-2-glycoprotein I expression on monocytes is increased in anti-phospholipid antibody syndrome and correlates with tissue factor expression. Clin Exp Immunol 2003; 132(3):509-16.
15. Atsumi T, Khamashta MA, Amengual O, Hughes GRV. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost 1997; 77(1):222-3.
16. Kubota T, Fukuya Y, Hashimoto R, Kanda T, Suzuki H, Okamura Y, et al. Possible involvement of chemokineinduced platelet activation in thrombophilic diathesis of antiphospholipid syndrome. An attractive target for the NF-κB-specific inhibitor DHMEQ. Ann N Y Acad Sci 2009; 1173:137-45.
17. Schäfer A, Schulz C, Eigenthaler M, Fraccarollo D, Kobsar A, Gawaz M, et al. Novel role of the membranebound chemokine fractalkine in platelet activation and adhesion. Blood 2004; 103(2):407-12.
18. Clemetson KJ, Clemetson JM, Proudfoot AEI, Power CA, Baggiolini M, Wells TNC. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000; 96(13):4046-54.
19. Suzuki Y, Sigiyama C, Ohno O, Umezawa K: Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor. Tetrahedron 2004; 60(33):7061-6.
20. Ushiyama A, Yamada S, Ohkubo C. Microcirculatory parameters measured in subcutabeous tissue of the mouse using a novel dorsal skinfold chamber. Microvasc Res 2004;68(2):147-52.
21. Yasuda S, Bohgaki M, Atsumi T, Koike T. Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway. Immunobiology 2005; 210(10):775-80.
22. Montiel-Manzano G, Romay-Penabad Z, de Martínez EP, Meillon-García LA, García-Latorre E, Reyes-Maldonado E, et al. In vivo effects of an inhibitor of nuclear factorkappa B on thrombogenic properties of antiphospholipid antibodies. Ann N Y Acad Sci 2007:1108:540-53.
23. Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K: Inactivation of NF-κB components by covalent binding of (–)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 2008; 51(18):5780-8.
24. Watanabe M, Nakashima M, Togano T, Higashihara M, Watanabe T, Umezawa K, et al. Identification of the RelA domain responsible for action of a new NF-κB inhibitor DHMEQ. Biochem Biophys Res Commun 2008; 376(2):310-4.
25. Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T. Effect of a small molecule inhibitor of nuclear factor-κB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005;7:R1348-59.
26. Kubota T, Hoshino M, Aoki K, Ohya K, Komano Y, Nanki T, et al. NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Arthritis Res Ther 2007;9:R97.
27. Kubota T, Umezawa K. Suppression of erosive arthritis by NF-κB inhibitors. Curr Rheumatol Rev 2011; 7(4):275-81.
28. Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res 2003; 63(1):107-10.
29. Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, et al. Potent cytotoxic effect of a novel nuclear factor-κB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines. Urology 2010;75(4):805-12.
30. Umezawa K. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci 2006; 97(10):990-5.